(Q40014590)

16 September 2017

1 reference

reason for preferred rank

title

3 The Chemistry of Guanidines and their Actions at Adrenergic Nerve Endings (English)

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

The chemistry of guanidines and their actions at adrenergic nerve endings (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A4992683

25 March 2023

author name string

G. J. Durant

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A4992683

25 March 2023

A. M. Roe

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A4992683

25 March 2023

A. L. Green

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A4992683

25 March 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=4992683

25 March 2023

publication date

1 January 1970

1 reference

Progress in medicinal chemistry

16 September 2017

published in

1 reference

16 September 2017

volume

7

1 reference

16 September 2017

issue

1

1 reference

16 September 2017

page(s)

124-213

1 reference

[2-Octahydro-1-azocinyl)-ethyl]-guanidine sulfate (CIBA 5864-SU), a new synthetic antithypertensive agents]

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

über Synthetisch Dargestellte Körper mit Insulinartiger Wirkung Auf den Normalen und Diabetischen Organismus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

ADRENERGIC NEURONE BLOCKING AGENTS.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

549. The basic strengths of methylated guanidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Acid-base titrations in concentrated guanidine hydrochloride. Dissociation constants of the guamidinium ion and of some amino acids

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Über einige Guanidoniumsalze

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Aryloxyalkylaminoguanidines. Their synthesis and biological properties

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The crystal structure of guanidinium chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The infra-red spectrum and structure of guanidine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Ultra-violet /Absorption Spectra of Simple Aliphatic Guanidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

[Metabolism of guanidyl derivatives. III. Chromatographic analysis of guanidyl derivatives]

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

[PAPER CHROMATOGRAPHY OF SEVERAL BIOLOGICALLY IMPORTANT GUANIDINE COMPOUNDS]

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

SPECTROPHOTOMETRIC METHOD FOR THE ESTIMATION OF GUANETHIDINE

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

A modified Sakaguchi spray

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Antiplasmodial action and chemical constitution; guanidines and diguanides.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Synthetic antimalarials; some 4-arylguanidino-2- and-6-dialkylaminoalkylaminopyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

THE SYNTHESIS AND PHARMACOLOGY OF SOME SUBSTITUTED 1,3-BENZODIOXOLES AND 1,4-BENZODIOXANS

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Adrenergic neurone blocking agents. II. Some dioxane-substituted derivatives of guanoxan

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Some alkoxy- and alkylenedioxydi-amines and alkoxy- and alkylenedioxydi-guanidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Hydroxylamine chemistry. V. Aralkoxyguanidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The synthesis of aryloxybiguanide and aryloxyguanidine salts

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

CCXIV.?The preparation of methylguanidine, and of ??-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Hypoglycemic Agents. I. 1 Chemical Properties of β-Phenethylbiguanide. 2 A New Hypoglycemic Agent 3

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

EXPERIMENTAL CHEMOTHERAPY OF TRYPANOSOMIASIS. II. THE PREPARATION OF COMPOUNDS RELATED TO p-PHENYLENEDIGUANIDINE

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

HYPOTENSIVES. V. 2,2,6,6-TETRAMETHYLPIPERIDINES AND RELATED COMPOUNDS

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Biologically active guanidines and related compounds. II. Some antiinflammatory aminoguanidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

POTENTIAL ANTIHYPERTENSIVE AGENTS. SOME GUANIDINE DERIVATIVES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

BACTERIOSTATS. VI. BACTERIOSTATIC ACTIVITIES OF SOME SUBSTITUTED GUANIDINES.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Adrenergic neurone blocking agents derived from 1,4-benzodioxan

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

SYMPATHETIC NERVOUS SYSTEM BLOCKING AGENTS. DERIVATIVES OF GUANIDINE AND RELATED COMPOUNDS

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Sympathetic Nervous System Blocking Agents. III. Derivatives of Benzylguanidine1-3

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The preparation of substituted 4-aminomethylpiperidines and their straight chain analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES WITH ANTIHYPERTENSIVE PROPERTIES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

SYNTHESES OF 2-GUANIDINO-2-METHYLPROPYLAMINE DERIVATIVES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

In-vitro formation of noradrenaline from dopamine by human tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Syntheses of Guanidino-substituted Penicillins and Cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

A new reagent for the guanidination of proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Synthesis of cis- and trans-2-phenoxycyclopropylamines and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

1,3-diethyleneguanidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The reaction of primary amines with 2-nitramino-delta2-1,3-diazacycloalkenes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

STUDIES ON METHYLGLYOXAL BIS(GUANYLHYDRAZONE) ANALOGS. I. HOMOLOGS OF METHYLGLYOXAL BIS(GUANYLHYDRAZONE)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

THE SYNTHESIS, PROOF OF STRUCTURE, AND BIOLOGICAL ACTIVITY OF SOME MONOSUBSTITUTED AMINOGUANIDINES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

A New Route to Substituted Guanidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Dual actions of some N-(1-phenylethyl)guanidines on the nictitating membrane of conscious cats.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

On the nature of inhibition in the intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Guanethidine and Hypertension After Five Years

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

STUDIES ON STRUCTURE-ACTIVITY RELATIONSHIPS OF GUANIDINE DERIVATIVES. I. SYNTHESIS AND PHARMACOLOGY OF AMINOETHYLGUANIDINE DERIVATIVES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The relationship between adrenergic neurone blocking activity and local anaesthetic activity in a series of guanidine derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

[Studies on structure-activity relationships of guanidine derivatives. II. Actions of aminoethylguanidine derivatives in adrenergic mechanisms]

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Sympathetic nervous system blocking agents. IV. Synthesis of 2-[2-(methylthio)ethylamino]ethylguanidine sulfate and related compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Derivatives of 2-azabicyclo[2.2.2]octane. I

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

SOME PHARMACOLOGICAL PROPERTIES OF A NEW ADRENERGIC NEURONE-BLOCKING AGENT, N-(BETA-GUANIDINOETHYL)-HEXAHYDROBENZO-(D)-AZOCINE SULPHATE (PH 881-7)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Sympathetic nervous system blocking agents. V. Derivatives of isobutyl-, tert-butyl-, and neopentylguanidine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Amidines as Adrenergic Neurone Blocking Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Adrenergic neurone-blocking agents related to choline 2, 6-xylyl ether bromide (TM 10), bretylium and guanethidine.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The Adrenergic Neurone Blocking Action of [2-(Methylphenylamino)ethyl]guanidine Sulfate.I

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The adrenergic neurone blocking action of [2-(methylphenylamino)-ethyl]guanidine sulfate. II.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

[The adrenergic neurone blocking action of [2-(methylphenylamino)ethyl] guanidine sulfate. 3. Study on sympathomimetic actions]

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Some New Adrenergic Neurone Blocking Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

CLINICAL TRIAL AND PHARMACOLOGICAL STUDY OF COMPOUND 1029. ("VATENSOL").

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Double-blind trial of four hypotensive drugs (methyldopa and three sympatholytic agents).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

CLINICAL TRIAL OF 2-GUANIDINOMETHYL (1,4) BENZODIOXAN (COMPOUND 1003).

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Clinical experience with bethanidine in treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Bethanidine, Guanethidine, and Methyldopa in Treatment of Hypertension: a Within-patient Comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

New Norepinephrine-Depleting Agents. β-Hydroxyphenethylguanidine and Related Compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Hypotensive activity ofcis-cinnamyl guanidine sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Antihypertensive activity of 7-azaindole-3-acetamidoxime and indole-1-acetamidoxime

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

CLINICAL PHARMACOLOGICAL STUDIES WITH DEBRISOQUIN SULFATE, A NEW ANTIHYPERTENSIVE AGENT.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Pharmacological Studies on Guanethidine Derivatives. IV. Adrenergic Neurone Blocking Action of 2, 3, 4, 5-Tetrahydro-1H-2-benzazepine-2-carboxamidine Sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Cardiovascular effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155). I. Peripheral sympathetic system.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Cardiovascular effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155). II. Central sympathetic structures.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorphenylamino)-2-imidazoline-HCl.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The structure of muscarine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Structure of Acetylcholine and Other Substrates of Cholinergic Systems

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Conformation of Xylocholine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

A comparison of aralkylamines and aralkylguanidines as antagonists of adrenergic neurone blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Antagonism of Bretylium by Sympathomimetic Amines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

VALIDITY OF PTOSIS AS A MEASURE OF THE CENTRAL DEPRESSANT ACTION OF RESERPINE.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

SOME EFFECTS OF DRUGS WHICH INFLUENCE SYMPATHETIC TRANSMISSION ON TISSUE CATECHOLAMINE LEVELS IN THE RAT.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Reserpine and guanethidine action on peripheral stores on catecholamines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Clinical and pharmacological studies with guanethidine in the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The distribution and excretion by cats of a new hypotensive drug, N-benzyl-N'N"-dimethylguanidine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Ultrastructural modifications induced by several drugs on adrenergic nerve endings and on the adrenal medulla

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Mitochondrial enzymes and chromaffin granules

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

RELEASE OF THYROIDAL SEROTONIN BY RESERPINE, METHYLDOPA AND GUANETHIDINE

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

THE UPTAKE OF ALPHA-METHYLNORADRENALIN INTO THE ISOLATED RABBIT HEART AND ITS LIBERATION BY RESERPINE AND GUANETHIDINE IN VIVO

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Mechanism of Norepinephrine Binding

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

THE EFFECTS OF GUANETHIDINE ON THE NORADRENALINE CONTENT OF THE HYPOTHALAMUS IN THE CAT AND RAT.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

RESERPINE-INDUCED RELEASE OF DRUGS FROM SYMPATHETIC NERVE ENDINGS

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The effects of bretylium and cocaine on noradrenaline depletion.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

MECHANISM OF AMINE TRANSPORT IN THE CELL MEMBRANES OF THE ADRENERGIC NERVES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

INHIBITION OF NORADRENALINE UPTAKE BY DRUGS.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Structural requirements for bretylium and guanethidine-like activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The effect of monoamine oxidase inhibition on guanethidine-induced noradrenaline release and sympathetic blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

On the mechanism of hypotensive effects of MAO inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

DOSE: RESPONSE EFFECTS ON NOREPINEPHRINE-DEPLETION OF RESERPINE AND OF GUANETHIDINE IN BRETYLIUM-PRETREATED RATS

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The bretylium-like effect of guanethidine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Reversal by amphetamine of the protective effect of bretylium on reserpine-induced depletion of noradrenaline.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Influence of guanethidine on the catecholamine depleting effects of tyramine in the rat heart

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

1 reference

7 January 2021

Inhibition of dopamine-beta-oxidase by diethyldithiocarbamate.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Histochemical amd biochemical effects of diethyldithiocarbamate on tissue catecholamines.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The activation and inhibition of phenylamine-beta-hydroxylase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Guanoclor as an antihypertensive drug

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Action of TM 10 (choline 2: 6-xylyl ether bromide) and its beta-methyl derivative on the conversion of dopamine to noradrenaline by chromaffin tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Selective brain monoamine oxidase inhibition resulting from an interaction between reversible and irreversible inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Studies in vitro of amine uptake mechanisms in heart

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

RESERPINE AND COCAINE BLOCKING OF THE UPTAKE AND STORAGE MECHANISMS IN ADRENERGIC NERVES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

SITE OF ACTION OF RESERPINE.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

EFFECTS OF BRETYLIUM, RESERPINE, GUANETHIDINE AND SYMPATHETIC DENERVATION ON THE NORADRENALINE CONTENT OF THE RAT SUBMAXILLARY GLAND

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

THE ACTIONS OF RESERPINE, GUANETHIDINE AND METARAMINOL ON CARDIAC CATECHOLAMINE STORES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Relationships between the release and tissue depletion of norepinephrine from the heart by guanethidine and reserpine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

EVIDENCE FOR DIFFERENT SITES OF ACTION OF RESERPINE AND GUANETHIDINE

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Kinetics of release of norepinephrine by tyramine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

THE UPTAKE AND RELEASE OF H3-NOREPINEPHRINE BY THE GUINEA-PIG HEART IN VIVO

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Effects of Drugs on Uptake of Isotopic Norepinephrine by Cat Tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

[THE EFFECT OF DRUGS ON THE ELIMINATION OF NORADRENALIN FROM PERFUSION FLUID AND NORADRENALIN UPTAKE IN THE ISOLATED HEART]

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Dual actions of guanethidine on amine uptake mechanisms in adrenergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Studies on the Dual Action of Guanethidine in Sympathetic Nerves

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Study of the relationship between the neurotransmitter store and adrenergic nerve block induced by reserpine and guanethidine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Release of Tritiated Bretylium by Sympathetic Nerve Stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Reduction of Nitroguanidine. III. Synthesis of Aminoguanidine1

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

GUANIDINES WITH ANTIHYPERTENSIVE ACTIVITY. II

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The chemorelease of norepinephrine in mouse hearts. Structure-activity relationships. II. Drugs affecting the sympathetic and central nervous systems

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Studies on the action of guanethidine on the central nervous system and on the norepinephrine content of the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Norepinephrine depletion as a possible mechanism of action of guanethidine (SU 5864), a new hypotensive agent

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

INHIBITION OF NORADRENALINE UPTAKE BY SYMPATHOMIMETIC AMINES

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The acute sensitization of tissues by choline 2:6-xylyl ether (TM 10), bretylium and guanethidine.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Guanacline, a new hypotensive drug

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Qualitative and quantitative thin-layer chromatography of guanidine derivatives and differentiation of phosphagens from other phosphorus compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Synthesis and antiviral properties of 1-adamantylguanidine. A modified method for preparing t-alkylguanidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

N-(beta-guanidinoethyl)- and N-guanylazetidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The preparation and properties of (+)- and (--)-guanoxan

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Adrenergic neurone blocking agents. 3. Heterocyclic analogs of guanoxan

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Hypotensive activity of some cyanoguanidines

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The isolation, identification and synthesis of two metabolites of guanethidine formed in pig and rabbit liver homogenates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Subcellular distribution of [3H]amphetamine and [3H]guanethidine and their interaction with adrenergic neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Mechanism of the antagonism between guanethidine and dexamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Some Studies on the Mechanism by which d-Amphetamine Antagonizes Guanethidine Induced Adrenergic Neurone Blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

Stimulus-secretion coupling: the concept and clues from chromaffin and other cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

The accumulation of guanethidine by human blood platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

On the physiological disposition and possible mechanism of the antihypertensive action of debrisoquin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2808%2970353-9

7 January 2021

9

200

30

Prichard

1968

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

Pharmacological Reviews

37

14

37

Pastier

1962

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Acid-Base Equilibria in Benzene at Three Temperatures. The Comparative Reactivities of a Phenolic Acid and a Carboxylic Acid with Triethylamine and with 1,3-Diphenylguanidine<sup>1</sup>

25 March 2023

40

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

70

1224

Mourgue

1955

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of the Pharmaceutical Society of Japan

25 March 2023

91

64

36

Kusami

1944

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of the Chemical Society

25 March 2023

103

1665

Royer

1949

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of the Chemical Society

25 March 2023

105

2722

Miller

1949

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

123

1062

Funke

1947

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

130

383

Lespagnol

1960

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

157

181

Mouigue

1948

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

190

556

Najer

1962

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

211

128

22

Maxwell

1960

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

233

161

88

Cummings

1968

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

234

124

127

Maxwell

1958

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

235

123

128

Maxwell

1958

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

236

134

347

Maxwell

1961

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

238

152

243

Botton

1966

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

253

143

374

Chen

1964

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

271

8

182

Barrett

1966

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

278

198

673

Gent

1967

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

279

198

723

Cranston

1967

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

315

148

320

Maxwell

1965

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

343

146

194

Shore

1966

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Biochimica et Biophysica Acta

25 March 2023

348

81

394

Green

1964

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

349

151

236

Distefano

1966

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

356

140

308

Porter

1963

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

357

144

196

Stone

1964

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

358

151

189

Thoenen

1966

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

366

140

199

Potter

1963

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

368

147

186

Kopin

1965

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

370

144

399

Kuntzman

1964

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

378

140

207

Kopin

1963

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

381

147

86

Spector

1965

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

388

1

69

Sheppard

1959

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

392

141

166

Kuntzman

1963

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

406

136

289

Hertting

1962

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

418

134

1

Gillis

1961

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

429

1593

Najer

1962

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

432

2118

Najer

1965

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

433

204

Najer

1965

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Journal of Pharmacology and Experimental Therapeutics

25 March 2023

440

135

164

Krayer

1962

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

448

202

294

Anon

1969

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

458

3965

Robin

1967

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

Polish Journal of Chemistry

25 March 2023

464

41

1087

Krug

1967

1 reference

https://api.crossref.org/works/10.1016/S0079-6468(08)70353-9

25 March 2023

Identifiers

0 references

1 reference